Hill-Rom Holdings Management Presents At Citi Global Health Care Conference (Transcript)

Hill-Rom Holdings, Inc. ( HRC)

Citi Global Health Care Conference

February 28, 2012 1:30 PM ET


Mark Guinan – CFO and SVP


Matt Miksic – Piper Jaffray


Matt Miksic – Piper Jaffray

Pleased to introduce Hill-Rom Holdings, we are going to do a hybrid of few slides and a fire side chat and we have got Mark on in, who is Senior Vice President and Chief Financial Officer and Andy Reith who is Vice President of Investor Relation, so Mark thank you and it's up to you.

Mark Guinan

Thanks Matt and thank you for joining us today. Welcome to the Hill-Rom presentation. First off I want to start out with some of the comments about forward-looking statements and the cautions about such statements, also that some of the figures, like you can see in the slides that I am going to refer to are on an ad adjusted basis. We do have reconciliations to the gap figures into the appendix of our decks.

So little bit about Hill-Rom Holdings, I know some of you are quite familiar with our story and some of you less off, so I will try to touch on both for those of you are very familiar and those who maybe and not so much.

We are a global leader in Medtech, across the care continue and what we mean by that is from the acute setting into the post-acute setting including extended care and home care. We have therapeutic products that are available both for sale, our capital business as well as for rent and we also have a service business as well. We have everything from our patient support systems which is more commonly to as our frames and surfaces, our beds and mattresses; you are probably familiar with, the patient lifts, architectural products and furniture.

If you liked this article you might like

7 Stocks Making Big Moves With Unusual Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: DHF, ENS, HRC

Hill-Rom (HRC) Stock Dives on Q2 Revenue Miss, Outlook

14 Cheap Stocks to Buy Now From Goldman Sachs

6 Medical Device Stocks to Treat the Bear Market Blues